medical device investing Pulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
medical device investing Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
medical device investing Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
medical device investing Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
medical device investing ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
medical device investing Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
medical device investing Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
medical device investing Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse Cardiac Catheter System at Heart Rhythm 2026
medical device investing Pulse Biosciences' nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
medical device investing Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation
medical device investing Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation
EraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR
